ACE-I |
angiotensin converting enzyme inhibitor |
ARB |
Angiotensin receptor blocker |
CHF |
Congestive heart failure |
CKD |
Chronic kidney disease |
CKRT |
continuous kidney replacement therapy |
CI |
confidence interval |
CV |
cardiovascular |
DKA |
diabetic keto acidosis |
DKD |
diabetic kidney disease |
ESKD |
end stage kidney disease |
eGFR |
estimated glomerular filtration rate |
ENaC |
Epithelial sodium channel |
GLP-1 |
glucagon like peptide-1 |
HR |
Hazard ratio |
HTN |
Hypertension |
KRT |
Kidney replacement therapy |
MI |
myocardial infarction |
MR |
mineralocorticoid receptor |
MRA |
mineralocorticoid receptor antagonist |
RAAS |
renin–angiotensin–aldosterone system |
SGLT2 |
sodium-glucose transport protein 2 |
T2DM |
type II diabetes mellitus |
UACR |
urine albumin to creatinine ratio |